REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 75.04 Billion KRW | 3.65% |
| 2022 | 72.4 Billion KRW | -5.22% |
| 2021 | 76.39 Billion KRW | 10.5% |
| 2020 | 69.13 Billion KRW | 4.17% |
| 2019 | 66.36 Billion KRW | 0.45% |
| 2018 | 66.06 Billion KRW | 16.62% |
| 2017 | 56.65 Billion KRW | 0.71% |
| 2016 | 56.25 Billion KRW | 19.31% |
| 2015 | 47.14 Billion KRW | 0.97% |
| 2014 | 46.69 Billion KRW | 1.37% |
| 2013 | 46.06 Billion KRW | -0.06% |
| 2012 | 46.09 Billion KRW | -15.96% |
| 2011 | 54.84 Billion KRW | 8.23% |
| 2010 | 50.67 Billion KRW | 39.25% |
| 2009 | 36.39 Billion KRW | 23.43% |
| 2008 | 29.48 Billion KRW | 26.11% |
| 2007 | 23.37 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.44 Billion KRW | 0.97% |
| 2024 Q2 | 17.06 Billion KRW | -2.15% |
| 2023 Q4 | 17.27 Billion KRW | 194.68% |
| 2023 Q2 | -17.74 Billion KRW | -195.91% |
| 2023 Q3 | -18.24 Billion KRW | -2.84% |
| 2023 FY | 75.04 Billion KRW | 3.65% |
| 2023 Q1 | 18.5 Billion KRW | 21.35% |
| 2022 Q4 | 15.24 Billion KRW | -14.05% |
| 2022 Q3 | 17.73 Billion KRW | -19.52% |
| 2022 Q1 | 17.09 Billion KRW | -5.31% |
| 2022 FY | 72.4 Billion KRW | -5.22% |
| 2022 Q2 | 22.03 Billion KRW | 28.91% |
| 2021 Q3 | 20.31 Billion KRW | 2.4% |
| 2021 Q1 | 18.14 Billion KRW | 8.1% |
| 2021 FY | 76.39 Billion KRW | 10.5% |
| 2021 Q2 | 19.83 Billion KRW | 9.34% |
| 2021 Q4 | 18.05 Billion KRW | -11.1% |
| 2020 Q3 | 17.76 Billion KRW | 8.1% |
| 2020 Q2 | 16.43 Billion KRW | -9.45% |
| 2020 Q1 | 18.15 Billion KRW | 3.83% |
| 2020 FY | 69.13 Billion KRW | 4.17% |
| 2020 Q4 | 16.78 Billion KRW | -5.53% |
| 2019 Q2 | 16.63 Billion KRW | 3.22% |
| 2019 Q4 | 17.48 Billion KRW | 8.34% |
| 2019 FY | 66.36 Billion KRW | 0.45% |
| 2019 Q1 | 16.11 Billion KRW | -19.06% |
| 2019 Q3 | 16.13 Billion KRW | -3.0% |
| 2018 Q3 | 15.71 Billion KRW | -6.7% |
| 2018 FY | 66.06 Billion KRW | 16.62% |
| 2018 Q4 | 19.9 Billion KRW | 26.69% |
| 2018 Q2 | 16.84 Billion KRW | 23.9% |
| 2018 Q1 | 13.59 Billion KRW | -10.73% |
| 2017 FY | 56.65 Billion KRW | 0.71% |
| 2017 Q4 | 15.22 Billion KRW | 6.55% |
| 2017 Q3 | 14.29 Billion KRW | 2.61% |
| 2017 Q2 | 13.92 Billion KRW | 5.07% |
| 2017 Q1 | 13.25 Billion KRW | -14.73% |
| 2016 Q3 | 14.05 Billion KRW | -1.82% |
| 2016 FY | 56.25 Billion KRW | 19.31% |
| 2016 Q4 | 15.54 Billion KRW | 10.6% |
| 2016 Q2 | 14.31 Billion KRW | 16.06% |
| 2016 Q1 | 12.33 Billion KRW | -5.37% |
| 2015 Q3 | 11.37 Billion KRW | -0.88% |
| 2015 Q4 | 13.03 Billion KRW | 14.6% |
| 2015 Q2 | 11.47 Billion KRW | 1.88% |
| 2015 Q1 | 11.26 Billion KRW | -5.02% |
| 2015 FY | 47.14 Billion KRW | 0.97% |
| 2014 Q4 | 11.85 Billion KRW | 0.72% |
| 2014 Q2 | 11.77 Billion KRW | 4.33% |
| 2014 Q1 | 11.28 Billion KRW | -8.1% |
| 2014 FY | 46.69 Billion KRW | 1.37% |
| 2014 Q3 | 11.77 Billion KRW | -0.02% |
| 2013 Q1 | 11.73 Billion KRW | -5.19% |
| 2013 Q2 | 11.24 Billion KRW | -4.17% |
| 2013 Q4 | 12.28 Billion KRW | 13.79% |
| 2013 Q3 | 10.79 Billion KRW | -4.06% |
| 2013 FY | 46.06 Billion KRW | -0.06% |
| 2012 FY | 46.09 Billion KRW | -15.96% |
| 2012 Q4 | 12.38 Billion KRW | 4.89% |
| 2012 Q3 | 11.8 Billion KRW | 1.97% |
| 2012 Q2 | 11.57 Billion KRW | 5.46% |
| 2012 Q1 | 10.97 Billion KRW | -31.1% |
| 2011 Q2 | 12.48 Billion KRW | 8.3% |
| 2011 Q1 | 11.53 Billion KRW | -15.45% |
| 2011 Q3 | 14.89 Billion KRW | 19.26% |
| 2011 Q4 | 15.93 Billion KRW | 6.98% |
| 2011 FY | 54.84 Billion KRW | 8.23% |
| 2010 Q3 | 12.89 Billion KRW | 4.45% |
| 2010 FY | 50.67 Billion KRW | 39.25% |
| 2010 Q2 | 12.34 Billion KRW | 0.0% |
| 2010 Q4 | 13.63 Billion KRW | 5.73% |
| 2009 FY | 36.39 Billion KRW | 23.43% |
| 2008 FY | 29.48 Billion KRW | 26.11% |
| 2007 FY | 23.37 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -58.821% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 74.815% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 73.046% |
| HANDOK Inc. | 153.76 Billion KRW | 51.193% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -8.431% |
| Yuhan Corporation | 489.94 Billion KRW | 84.682% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 75.551% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -79.589% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 87.716% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -4.259% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 56.905% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -87.374% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 19.778% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 34.583% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -58.821% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -76.704% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -27.974% |
| JW Holdings Corporation | 301.25 Billion KRW | 75.088% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 71.241% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 81.635% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 68.587% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 41.216% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -9.864% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -14.141% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 57.097% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -58.821% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 69.875% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 86.609% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 68.587% |
| Yuhan Corporation | 489.94 Billion KRW | 84.682% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 61.248% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -8.033% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -33.94% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 68.587% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 40.622% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 36.514% |
| CKD Bio Corp. | 25.19 Billion KRW | -197.864% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 66.194% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 54.547% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -12.996% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 41.216% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 78.601% |
| Boryung Corporation | 285.16 Billion KRW | 73.682% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 14.271% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 56.905% |
| JW Lifescience Corporation | 20.26 Billion KRW | -270.402% |